Biotech entity
Every one of those 1 sits in a single category, clinical-trial. Grok is most often covered alongside Elon Musk, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Grok, all published on August 12, 2026.
Last mentioned: Aug 14, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Grok is most often covered alongside Elon Musk, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Grok, all published on August 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 11 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Grok. Shared-story counts are live from our verified record — not editorial picks.
While SpaceX’s record IPO captures headlines, Neuralink remains Musk’s most medically transformative—and least proven—venture. Brain-computer interface technology could revolutionize treatment for neurological disorders, but faces immense regulatory, clinical, and funding challenges. The empire’s financial coherence may dictate how fast this biotech moonshot advances.
Grok is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
